Kiromic BioPharma, Inc. (KRBP)
Stock Price:
$11.29 USD
-0.21 (-1.83%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
56.33M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-16.28M |
| Shares Out |
7.33M |
| EPS (ttm) |
-2.22 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$11.29 |
| Previous Close |
$11.50 |
| Change ($) |
-0.21 |
| Change (%) |
-1.83% |
| Day's Open |
11.20 |
| Day's Range |
10.75 - 11.50 |
| Day's Volume |
119,034 |
| 52-Week Range |
10.30 - 11.90 |
More Stats
| Market Cap |
56.33M |
| Enterprise Value |
54.76M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
7.33M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-2.22 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
26.88 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-16.28M |
| Free Cash Flow |
n/a |
| Net Cash |
1.57M |
| Net Cash / Share |
0.31 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -3.68 | -2.55 |
| Net Income | -3.73 | -3.82 |
| Shares Outstanding | 2.86 | 2.86 |
| Earnings Per Share | -1.39 | -1.33 |
| Operating Cash Flow | -2.91 | -2.15 |
| Capital Expenditures | -0.30 | -0.14 |
| Free Cash Flow | -3.22 | -2.29 |
| Cash & Equivalents | 1.93 | 0.38 |
| Net Cash / Debt | 1.93 | 0.38 |
| Assets | 2.65 | 0.88 |
| Liabilities | 0.67 | 0.61 |
| Book Value | 1.98 | 0.27 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Kiromic BioPharma, Inc. |
| Country |
United States |
| Employees |
13 |
| CEO |
Maurizio Chiriva-Internati |
Stock Information
| Ticker Symbol |
KRBP |
| Stock Exchange |
NASDAQ |
| Sector |
Health Technology |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KRBP |
| IPO Date |
October 16, 2020 |
Description
Kiromic BioPharma is a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology. Our proprietary target discovery engine is called "Diamond." Kiromic's Diamond is big data science meeting target identification, dramatically compressing man-years and billions of drug development dollars to develop a live drug. Without Kiromic's Diamond, the management of all the data required to solve the Target Identification puzzle is both challenging and inefficient. Normal data required for target identification would require manual analysis of thousands of cancer tissue samples with billions of data points, looking at millions of mutations, and poring over thousands of publications on oncology and targets.